Saama Launches AI Tool that Automates Data Quality Checks
Data quality co-pilot considered the first of its kind.
Saama, an artificial intelligence (AI) solutions provider, has introduced a data quality (DQ) co-pilot, a feature embedded directly into its Smart Data Quality (SDQ) tool, that quickly generates code for simple to complex, cross-domain data quality checks and tests them using generative artificial intelligence (GenAI). According to the company, the product has the potential to significantly accelerate clinical development by eliminating the need to manually program, test, and deploy data quality checks.
“Generative AI and its application in clinical data management is transforming our approach to the visualization and analysis of clinical trial data,” said Malaikannan Sankarasubbu, VP, AI Research, Saama. “The time and effort saved using Saama’s embedded DQ co-pilot is empowering clinical development by enabling faster trail setup and giving precious time back to data managers. This time can be used to support more studies and focus their talent on higher-value activities, all with the goal to get new treatments to patients more quickly.”
Reference: Saama Introduces Industry’s First Generative AI Tool to Automate Data Quality Checks. Saama. September 19, 2023. Accessed September 20, 2023. https://www.saama.com/news/saama-introduces-industrys-first-generative-ai-toolto-automate-data-quality-checks/
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
